Phase 2A of Mumbai Metro Line 3—also called the Aqua Line—is now in its final stage. This new stretch will connect Bandra-Kurla Complex (BKC) to Acharya Atre Chowk in Worli. As per the Free Press ...

Fares range from Rs 10 to Rs 50 for a one-way ride. Meanwhile, Phase 2 of Metro Line 3, which extends the route from Dharavi to Acharya Atre Chowk in Worli, is in the final stages of preparation.

Schizophrenia drug Cobenfy, a key component in Bristol Myers Squibb’s plan to navigate a transition period of major loss of exclusivity, has hit a phase 3 setback. Cobenfy as an adjunctive ...

Two novel peptides derived from Protagonist's proprietary discovery platform are currently in advanced Phase 3 clinical development, with New Drug Application submissions to the FDA potentially in ...

Additionally, a phase 3 trial evaluating the combination is planned, pending feedback from an FDA end-of-phase 2 meeting. “This is one of the strongest data set ever seen in an all-comer population of ...

Mark Huffman has been a consumer news reporter for ConsumerAffairs since 2004. He covers real estate, gas prices and the economy and has reported extensively on negative-option sales. He was ...

Eli Lil­ly re­port­ed the first Phase 3 da­ta for its oral GLP-1 or­for­glipron Thurs­day morn­ing, say­ing the drug suc­ceed­ed in a type 2 di­a­betes tri­al … ...

Ironwood Pharmaceuticals shares sank after the company said it needs to conduct a confirmatory phase 3 trial of proposed short-bowel treatment apraglutide. The stock hit a 52-week low in mid ...

Enriqueta Felip, MD, PhD, discusses the design of the phase 3 3475A-D77 trial evaluating subcutaneous pembrolizumab in metastatic NSCLC. Enriqueta Felip, MD, PhD, the Universitat Autònoma de Barcelona ...

PRINCETON, N.J.--(BUSINESS WIRE)--$BMY #Camzyos--Bristol Myers Squibb (NYSE: BMY) today announced the Phase 3 ODYSSEY-HCM trial evaluating Camzyos (mavacamten) for ...

Unfortunately you've used all of your gifts this month. Your counter will reset on the first day of next month.

Tem­pest Ther­a­peu­tics is mulling its busi­ness op­tions, in­clud­ing po­ten­tial ex­it path­ways, af­ter an in­abil­i­ty to raise cash to bankroll its lead can­cer as­set ...